

1-1-2022

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity

Anasha Kawall
Philadelphia College of Osteopathic Medicine

Devin S M Lewis
Philadelphia College of Osteopathic Medicine

Avini Sharma
Philadelphia College of Osteopathic Medicine

Krishna Chavada
Philadelphia College of Osteopathic Medicine

Rahul Deshmukh

See next page for additional authors

Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers

 Part of the [Pharmacy and Pharmaceutical Sciences Commons](#)

Recommended Citation

Kawall, Anasha; Lewis, Devin S M; Sharma, Avini; Chavada, Krishna; Deshmukh, Rahul; Rayalam, Srujana; Mody, Vicky; and Taval, Shashidharamurthy, "Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity" (2022). *PCOM Scholarly Papers*. 2182.

https://digitalcommons.pcom.edu/scholarly_papers/2182

This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by an authorized administrator of DigitalCommons@PCOM. For more information, please contact jaclynwe@pcom.edu.

Authors

Anasha Kawall, Devin S M Lewis, Avini Sharma, Krishna Chavada, Rahul Deshmukh, Srujana Rayalam, Vicky Mody, and Shashidharamurthy Taval



OPEN ACCESS

EDITED BY

Wagdy Mohamed Eldehna,
Kafrelsheikh University, Egypt

REVIEWED BY

Ahmed A. Al-Karmalawy,
Ahrum Canadian University, Egypt
Zhonglei Wang,
Qufu Normal University, China
Liyang Yang,
Qufu Normal University, China

*CORRESPONDENCE

Shashidharamurthy Taval,
✉ rangaiash@pcom.edu
Vicky Mody,
✉ vickymo@pcom.edu

SPECIALTY SECTION

This article was submitted to Medicinal and
Pharmaceutical Chemistry,
a section of the journal
Frontiers in Chemistry

RECEIVED 23 November 2022

ACCEPTED 26 December 2022

PUBLISHED 12 January 2023

CITATION

Kawall A, Lewis DSM, Sharma A, Chavada K,
Deshmukh R, Rayalam S, Mody V and
Taval S (2023), Inhibitory effect of
phytochemicals towards SARS-CoV-
2 papain like protease (PLpro) proteolytic
and deubiquitinase activity.
Front. Chem. 10:1100460.
doi: 10.3389/fchem.2022.1100460

COPYRIGHT

© 2023 Kawall, Lewis, Sharma, Chavada,
Deshmukh, Rayalam, Mody and Taval. This
is an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Inhibitory effect of phytochemicals towards SARS-CoV-2 papain like protease (PLpro) proteolytic and deubiquitinase activity


Anasha Kawall¹, Devin S. M. Lewis², Avini Sharma¹,
Krishna Chavada³, Rahul Deshmukh⁴, Srujana Rayalam³,
Vicky Mody^{3*} and Shashidharamurthy Taval^{3*}

¹Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine—Georgia Campus, Suwanee, GA, United States, ²Division of Research, Philadelphia College of Osteopathic Medicine—Georgia Campus, Suwanee, GA, United States, ³Department of Pharmaceutical Sciences, School of Pharmacy, Philadelphia College of Osteopathic Medicine—Georgia Campus, Suwanee, GA, United States, ⁴Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States

Recent studies have shown that RNA-dependent RNA polymerase (RdRp), 3-chymotrypsin-like protease (3CLpro), and papain-like protease (PLpro) are necessary for SARS-CoV-2 replication. Among these three enzymes, PLpro exhibits both proteolytic and deubiquitinase (DUB) activity and is responsible for disrupting the host's innate immune response against SARS-CoV-2. Because of this unique property of PLpro, we investigated the inhibitory effects of phytochemicals on the SARS-CoV-2 PLpro enzyme. Our data indicates that the phytochemicals such as catechin, epigallocatechin gallate (EGCG), mangiferin, myricetin, rutin, and theaflavin exhibited inhibitory activity with IC₅₀ values of 14.2, 128.4, 95.3, 12.1, and 43.4, and 7.3 μM, respectively, towards PLpro proteolytic activity. However, the IC₅₀ values of quercetin, oleuropein, and γ-mangostin are ambiguous. We observed that EGCG, mangiferin, myricetin, oleuropein, rutin, and theaflavin have also inhibited the DUB activity with IC₅₀ values of 44.7, 104.3, 29.2, 131.5, 61.7, and 13.2 μM, respectively. Mechanistically, the ligand-protein interaction structural modeling suggests that mangiferin, EGCG, theaflavin, and oleuropein shows that these four ligands interact with Glu¹⁶⁷, and Tyr²⁶⁸, however mangiferin and oleuropein showed very weak interaction with Glu¹⁶⁷ as compared to EGCG, and theaflavin which reflects their low IC₅₀ values for DUB activity. Our data indicate that the phytochemicals mentioned above inhibit the proteolytic and DUB activity of SARS-CoV-2 PLpro, thus preventing viral replication and promoting host innate immune response. However, the therapeutic potential of these phytochemicals needs to be validated by pre-clinical and clinical studies.

KEYWORDS

SARS-CoV-2, PLpro, replication, phytochemicals, natural compounds



Introduction

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease 19 (COVID-19) pandemic that claimed millions of lives globally (<https://coronavirus.jhu.edu/>). SARS-CoV-2 belongs to β -CoVs family and has single-stranded RNA as a source of genetic material (Ul Qamar et al., 2020). The virus's life cycle begins with its spike proteins attaching to the host cells' angiotensin-converting enzyme 2 (ACE2) receptor (Astuti and Ysrafil, 2020). After attachment, the viral envelope undergoes membrane fusion with the host cell membrane, which permits the release of the viral genome into the host cell's cytoplasm (Jackson et al., 2021). The viral genome (+ssRNA) uses the host's ribosomes to translate a polypeptide chain (PP) of approximately 800 kDa¹¹. Two proteases encoded by the viral genome, papain-like proteases (PLpro) and 3-chymotrypsin-like protease (3CLpro), auto-cleave the newly generated PP chain to generate 16 non-structural proteins (NSPs) required for the viral replication (Mody et al., 2021).

Along with protease activity, SARS-CoV-2 PLpro exhibits deubiquitination (DUB) activity (Mahmoudvand and Shokri, 2021). Ubiquitination refers to the attachment of ubiquitin (UB) and ubiquitin-like proteins (UBL) to the cellular proteins that need to be degraded by the host proteasomal complex in the cytosol. Ubiquitination also plays a vital role in degrading the foreign proteins such as viral proteins upon infection to prevent viral propagation (Kikkert, 2020); thus, SARS-CoV-2 PLpro's DUB activity disrupts the host's antiviral immune response. Upon viral infection, innate immune cells produce Type-I interferon (IFN- α/β), inducing interferon-sensitive gene-15 (ISG-15). The upregulated ISG-15 protein conjugates with multiple signaling molecules, such as JAK, STAT, and IRF-3, through ISGylation to promote the Type-I IFN

induced antiviral function (Jeon et al., 2010; Ratia et al., 2014; McClain and Vabret, 2020). It has been shown that SARS-CoV-2 PLpro mediates de-ISGylation of ISG-15 to the host signaling molecules that lead to the inhibition of the host antiviral innate immune response (McClain and Vabret, 2020; Shin et al., 2020). Thus, the SARS-CoV-2 PLpro's DUB activity impairs the primary interferon-mediated antiviral response, which is the main feature of COVID-19 (Yang et al., 2021). Numerous reports suggest that the SARS-CoV-2 mediated mortality is caused by the pro-inflammatory cytokine storm (Hojojo et al., 2020). The causation of the pro-inflammatory cytokine storm typical in SARS-CoV-2 infection may be due to the impaired interferon-mediated antiviral response. Thus, PLpro serves as a drug target to inhibit viral replication and suppress the cytokine storm during SARS-CoV-2 infection.

The effective measures, such as vaccines (Tomalka et al., 2022) and small-molecule inhibitors (Wang and Yang, 2020; Wang and Yang, 2022a; Calleja et al., 2022; Lv et al., 2022) are greatly needed to reduce SARS-CoV-2 transmission. However, promising drugs still do not exist (Wang et al., 2022a; Wang and Yang, 2022b; Rubin, 2022). As an indispensable resource, phytochemicals (Beura et al., 2021; Kumar et al., 2021; Wang and Yang, 2021; Wang et al., 2022b) have demonstrated potential value in countering SARS-CoV-2 infection. Phytochemicals have been used as natural antiviral compounds that can inhibit viral replication or viral entry (Cheng et al., 2006; Lin et al., 2014; Chakravarti et al., 2021; Srinivasan et al., 2022). They are derived from plants, vegetables, fruits, tea, and red wine and are used in traditional medicines. Phytochemicals were shown to inhibit viral replication, RNA synthesis, viral protein synthesis, and block viral attachment to the host cell (Cheng et al., 2006; Lin et al., 2014; Chakravarti et al., 2021; Srinivasan et al., 2022). In

the present study, we have investigated the inhibitory effect of several commercially available phytochemicals against the PLpro enzymatic activity assay. Some of the phytochemicals such as myricetin (extracted from nuts, berries, and red wine), theaflavin (extracted from black tea), mangiferin (extracted from mangoes), oleuropein (extracted from olives), EGCG (extracted from green tea) and rutin (extracted from buckwheat) exhibited more than 50% inhibition activity in SARS-CoV-2 PLpro enzymatic activity. These results suggest their potential benefit in preventing the replication of the SARS-CoV-2.

Materials and methods

Reagents and phytochemicals

Molecular biology grade DMSO was from Sigma-Aldrich (St. Louis, MO, United States). Sterile PBS was purchased from ThermoFisher Scientific (Waltham, MA, United States). Recombinant full-length untagged PLpro with His-Tag (SARS-CoV-2), assay buffers, inhibitors, fluorescently labeled substrates, and deubiquitinase substrates were from BPS Biosciences (San Diego, CA, United States). The phytochemicals were purchased from Sigma-Aldrich (St. Louis, MO), MedChemExpress (Princeton, NJ), and Cayman Chemicals (Ann Arbor, MI). The names of the phytochemicals, manufacturer names, and catalog numbers are listed in [Supplementary Table S1](#).

High-throughput screening enzymatic assays

Phytochemicals stock (8 mM) was prepared using either DMSO or PBS. Each phytochemical working stock (250 and 500 μM) was prepared in PBS and used for *in vitro* enzymatic assay. PLpro proteolytic and DUB assay were performed as described previously ([Lewis et al., 2022](#)). Briefly, 0.4 ng/ μL of PLpro in 30 μL of assay buffer was pre-incubated with the 10 μL of 250 μM phytochemicals for 1 hour. The enzymatic reaction was initiated by adding 10 μL of 250 μM fluorescently labeled substrate. The deubiquitinase assay was initiated using PLpro-specific ubiquitinated substrate incubated for 24 h s at room temperature under dark. Fluorescent reading was taken at 360/40 excitation and 460/40 nm emission using Synergy HT fluorescent plate reader. For dose-dependent studies, compounds were screened from concentrations of 0–100 μM . 10 μL of 1% DMSO with enzyme and 50 μM of substrate served as the positive control. Wells with 50 μM of GRL0617 compounds (BPS Biosciences) served as specificity controls. Wells with only 1% DMSO and 50 μM of substrate served as blank. All the values were subtracted from blank values to calculate the percent activity of the enzymes.

Cell viability assay

The cytotoxic effect of selected phytochemicals were carried out with Vero-E6 cells using PrestoBlue™ Cell Viability kit as described earlier ([Lewis et al., 2022](#)). Briefly, Vero-E6 cells (20,000 cells) were seeded overnight in 96 well plates. Then, 100 μL of complete media (EMEM+10% FBS+1%Pen/Strep) was added to refresh the cells along

with 50, 100, and 200 μM selected phytochemicals, and incubation was continued for 24, 48, and 72 hs at 37°C respectively. Cytotoxicity detection reagent (PrestoBlue solution) was added and incubated for additional 1h at 37°C. The absorbance was taken at 530/25 excitation and 590/35 nm emission using Bio-Tek Synergy HT fluorescent plate reader.

Preparation of phytochemicals and PLpro protein for computational studies

Molecular Operating Environment (MOE) 2020.09 was used to conduct molecular docking *in silico* studies using the Amber10:EHT forcefield. The crystal structure of SARS-CoV-2 PLpro was retrieved from the protein data bank (www.rcsb.org) with PDB format (ID: 7CMD) and was prepared with the MOE QuickPrep application under default settings. The selected phytochemicals were prepared with the program ChemDraw Professional, Version 10, Cambridge Soft.

Integrated Computer-Aided Molecular design computing method MOE was used to dock both phytochemicals with PLpro. All phytochemicals were examined individually and refined with the Triangle Matcher placement method and induced fit protocol. The docked molecules were scored with the GBVI/WSA dG scoring function.



Statistical analysis and reproducibility

Statistical analysis was carried out using one-way analysis of variance (ANOVA) with Bonferroni's Multiple Comparison test with 99.9% confidence intervals and represented as the mean \pm SEM. Two-way ANOVA was conducted with Dunnett's post-test to compare the grouped data. *p* values $p < .05$ considered statistically significant. Non-linear regression (curve fit) with four variable dose vs. inhibition was performed to calculate the IC_{50} values. GraphPad Prism (version 8; La Jolla, CA, United States) was used for statistical analysis. Four individual experiments were performed and triplicates are included in each experiment for reproducibility.

Results

Inhibition of SARS-CoV-2 PLpro proteolytic activity by phytochemicals

Since phytochemicals are known to inhibit viral replication or viral entry, we performed the high throughput screening of a series of phytochemicals, selected based on the literature review, towards SARS-CoV-2 PLpro proteolytic activity ([Supplementary Table S2](#)). Our data suggest that nine out of the 53 selected phytochemicals have the potential to inhibit SARS-CoV-2 PLpro proteolytic activity at least by 50% or lower when compared to untreated samples. [Figure 1A](#) reveals that only colchicine out of all the tested alkaloids such as chelidone, evodiamine, lycorine, sophocarpine and tetrandrine, could inhibit PLpro proteolytic activity. Colchicine was able to inhibit around 50% of the proteolytic activity at 200 μM . The four xanthone compounds tested were α , β , and γ -mangostin and mangiferin. Only γ -mangostin and mangiferin exhibited more than 50% inhibitory activity at the higher concentration (200 μM) against SARS-CoV-2 PLpro proteolytic activity






FIGURE 3

Inhibition of proteolytic activity of SARS-CoV-2 PLpro enzyme by selected miscellaneous phytochemicals. Miscellaneous phytochemicals were selected and screened for their inhibitory activity against the SARS-CoV-2 PLpro enzyme as described under Materials and Methods. The fluorescence intensity was used to calculate the percent proteolytic activity considering DMSO treated control as 100% activity. Blank values were subtracted before calculating the percent activity. Representatives of four individual experiments ($n = 4$) with triplicate values were presented graphically and analyzed using GraphPad Prism 8. p -values $< .05$ considered as statistically significant compared to the DMSO control.




FIGURE 4

Selected phytochemicals Flavanols (A), Flavonones (B), Miscellaneous Drugs (C), and Xanthenes (D) that exhibited inhibitory effect against deubiquitinase (DUB) activity of SARS-CoV-2 PLpro enzyme. Phytochemicals that inhibited the proteolytic activity of SARS-CoV-2 PLpro enzyme were selected and screened for their inhibitory effect towards DUB activity as described under Materials and Methods. The fluorescence intensity was used to calculate the percent DUB activity considering DMSO treated control as 100% activity. Blank values were subtracted before calculating the percent activity. Representatives of four individual experiments ($n = 4$) with triplicate values were presented graphically and analyzed using GraphPad Prism 8. p -values $< .05$ considered as statistically significant compared to the DMSO control.

(Figure 1B). We observed that the terpenoids such as artemisinin, betulinic acid, glycyrrhizic acid, obacunone, and organosulfur compounds, including diallyl disulfide and diallyl trisulfide, did not show inhibitory activity towards SARS-CoV-2 PLpro proteolytic activity at all the tested concentrations (Figure 1D).

All flavanols (Figure 2A), including catechin, EGCG, and theaflavin, exhibited a significant decrease in proteolytic activity. The inhibitory effect of catechin was 25%, 44%, and 64%, EGCG was 65%, 81%, and 97%, and

theaflavin had an average of 94%, 100% at 50, 100, and 200 μM . We observed that none of the tested isoflavone compounds such as daidzein, daidzin, genistein, genistin, and isoflorentin demonstrated an inhibitory effect against PLpro proteolytic activity at the tested doses (Figure 2B). As shown in Figure 2C, flavanones such as myricetin inhibited 96% at as low as 50 μM . Interestingly, quercetin inhibited 50% at 50 μM , and its inhibitory effect did not alter at higher concentration of 200 μM . Rutin exhibited 70% inhibitory activity at 50 and 100 μM and 88% at




FIGURE 5

Dose-dependent inhibition of SARS-CoV-2 PLpro proteolytic activity by EGCG, catechin, myricetin, mangiferin, and γ -mangostin, oleuropein, quercetin, rutin, and theaflavin: The phytochemicals that exhibited at least 50% inhibition of proteolytic activity of PLpro enzyme were selected and screened for their dose-dependent inhibitory activity as described under Materials and Methods. The fluorescence intensity was used to calculate the percent enzymatic activity considering DMSO treated control as 100% activity. Blank values were subtracted before calculating the percent activity. Representatives of four individual experiments ($n = 4$) with triplicate values were analyzed using GraphPad Prism8 and presented graphically. IC₅₀ values were calculated using non-linear regression (curve fit) with four variable dose vs. inhibition by GraphPad Prism8.

200 μ M. Nonetheless, none of the miscellaneous agents (Figure 3) except oleuropein and rosmarinic acid exhibited significant inhibition of the proteolytic activity of SARS-CoV-2 PLpro (60% and 50% at 200 μ M).

Inhibition of SARS-CoV-2 PLpro deubiquitinase activity by selected phytochemicals

Previous data revealed that catechin, EGCG, theaflavin, myricetin, quercetin, rutin, oleuropein, γ -mangostin, and mangiferin inhibited proteolytic activity of PLpro enzyme, and therefore, we performed DUB activity in the presence of these inhibitory phytochemicals. As shown in Figure 4A, flavanols such as catechin inhibited the DUB activity by 30%, 40%, and 50%, whereas, EGCG by 70%, 90%, and 95%, at 50, 100, and 200 μ M, respectively. Interestingly, theaflavin exhibited complete inhibition of DUB activity at concentration as low as 50 μ M. Flavonones (myricetin, quercetin, and rutin) were selected to test for potential inhibitory activity against SARS-CoV-2 PLpro's deubiquitinase activity. Figure 4B suggests that myricetin inhibited DUB activity by 60%, 90%, and 100% at 50, 100, and 200 μ M, respectively, whereas quercetin and rutin exhibited minimal inhibitory (20%–40%) activity against DUB activity of PLpro at the tested doses. Oleuropein was the only polyphenol compound classified as

miscellaneous agent that exhibited partial inhibitory activity (50% at 200 μ M) against SARS-CoV-2 PLpro's DUB activity (Figure 4C). Interestingly, xanthones such as γ -mangostin (50%) and mangiferin exhibited (70%) inhibitory activity towards the proteolytic activity of the PLpro enzyme (Figure 1B), but we observed very minimal DUB inhibitory activity (10%–30%) even at 200 μ M concentration (Figure 4B). At present we do not know the reason for the difference in the inhibitory activity of γ -mangostin and mangiferin against proteolytic and DUB activity of SARS-CoV-2 PLpro enzyme. The higher inhibitory effect of mangiferin towards proteolytic activity of PLpro might be due to the presence glycosidic unit compared to γ -mangostin, as we observed with Aloin-A and B (29).

Dose-dependent inhibition of proteolytic and DUB activity of SARS-CoV-2 PLpro enzymatic activity

Phytochemicals that exhibited more than 50% inhibitory activity against proteolytic and DUB activity of SARS-CoV-2 PLpro enzyme were tested for dose-dependent inhibitory effects to determine the concentration required to inhibit the 50% of enzymatic activity (IC₅₀). Here we represent the IC₅₀ values of the selected phytochemicals that exhibited inhibitory




FIGURE 6

Dose-dependent inhibition of SARS-CoV-2 PLpro DUB activity by EGCG, mangiferin, myricetin, oleuropein, rutin, and theaflavin: The phytochemicals that exhibited at least 50% inhibition of DUB activity of PLpro enzyme were selected and screened for their dose-dependent inhibitory activity as described under Materials and Methods. The fluorescence intensity was used to calculate the percent enzymatic activity considering DMSO treated control as 100% activity. Blank values were subtracted before calculating the percent activity. Representatives of four individual experiments ($n = 4$) with triplicate values were analyzed using GraphPad Prism8 and presented graphically. IC₅₀ values were calculated using non-linear regression (curve fit) with four variable dose vs. inhibition by GraphPad Prism8.





FIGURE 7

Interaction of selected phytochemicals with SARS-CoV-2 PLpro. (A) Interaction of EGCG with Glu¹⁶⁷, Cys¹¹¹ and Tyr²⁶⁸ of PLpro through hydrogen bonding. (B) Interaction of mangiferin with Tyr²⁶⁸ and Lys¹⁵⁷ of PLpro through hydrogen bonding. (C) Interaction of oleuropein with Tyr²⁶⁸ of PLpro through hydrogen bonding. (D) Interaction of Theaflavin with Tyr²⁶⁸ and Glu¹⁶⁷ of PLpro through hydrogen bonding. Site view and ligand interaction maps were presented to illustrate the hydrogen bonding.



activity against the PLpro enzyme. As shown in the [Figure 5](#), catechin, EGCG, myricetin, mangiferin, rutin, and theaflavin exhibited IC_{50} values of 14.2, 128.4, 12.1, 43.4, 95.3, and 7.3 μ M, respectively towards PLpro proteolytic activity. However, the IC_{50} values γ -mangostin, oleuropein, and quercetin are ambiguous. We observed that EGCG, mangiferin, myricetin, oleuropein, rutin, and theaflavin have IC_{50} values of 44.7, 104.3, 29.2, 131.5, 61.7, and 13.2 μ M, respectively for DUB activity ([Figure 6](#)).

Furthermore, we investigated the cytotoxic effect of EGCG, mangiferin, myricetin, oleuropein, rutin, and theaflavin since they exhibited inhibitory activity for both proteolytic and DUB activity of PLpro. Out of the six phytochemicals tested, four of them did not have cytotoxic effect on Vero-E6 for 24, 48, and 72 h s at 50, 100, and 200 μ M, respectively. However, we observed minimal cytotoxic effect (20%–30%) from myricetin and oleuropein after 48 hs ([Supplementary Figure S1](#)). We selected Vero-E6 cell line because of its sensitivity towards SARS-CoV-2 infection ([Ren et al., 2006](#); [Asrani et al., 2021](#)). Although selected phytochemicals exhibited minimal cytotoxic effects, it is possible that the cytotoxic effects of phytochemicals might be altered in the virus infected cells, therefore it is warranted that the effective concentration of these phytochemicals may change during viral challenge studies.

Structural interaction of phytochemicals with SARS-CoV-2 PLpro

The structure of SARS-CoV-2 PLpro is divided into four main sub-domains, the N-terminal Ubiquitin-like domain, α -helical thumb domain, β -stranded finger domain and the palm domain. The structure of ubiquitin-specific proteases deubiquitinating enzyme (DUB) shares a low homology (10%) ([Osipiuk et al., 2021](#)) with that of SARS-CoV-2 PLpro. The fingers subdomain is made of six β -

strands and two α -helices, whereas, the thumb comprises six α -helices and a small β -hairpin. The palm subdomain is comprised of six β -strands. The proteolytic and DUB sites in SARS-CoV-2 PLpro are independent of each other implying two possible activities of PLpro. The interface of palm and thumb subdomains is the location for conventional catalytic triad Cys¹¹¹-His²⁷²-Asp²⁸⁶. In addition to the catalytic triad, three additional residues play an important role in the enzymatic activity of SARS-CoV-2 PLpro: β -turn/loop (Glu²⁶⁶-Gly²⁷¹) which closes upon substrate and/or inhibitor binding is found adjacent to the active site. The Tyr²⁶⁸ part of the (Glu²⁶⁶-Gly²⁷¹) plays a critical role in the proteolytic activity of SARS-COV-2 PLpro and the Glu¹⁶⁷ in SARS-COV-2 PLpro plays an important role in ubiquitin core recognition. The mutation of Tyr²⁶⁸ has shown to interfere with the proteolytic activity of SARS-COV-2 PLpro and the mutations of Glu¹⁶⁷ causes a significant loss of DUB activity ([Osipiuk et al., 2021](#)). Any molecule which forms hydrogen bond with Tyr²⁶⁸ or Glu¹⁶⁷ will interfere with the proteolytic and the DUB activity of the SARS-CoV-2 PLpro, respectively and hence will show inhibitory activity.

The interaction of EGCG, mangiferin, myricetin, oleuropein, theaflavin, and rutin to the ligand site of GRL-0617, in the SARS-COV-2 PLpro (PDBID: 7cmd) was analyzed using MOE software. Molecular docking studies of EGCG, mangiferin, myricetin, oleuropein, theaflavin, and rutin with PLpro showed that myricetin and rutin did not interact with the catalytic site of PLpro enzyme and hence we were not able to obtain any docking studies for them and these molecules are not discussed further in molecular docking studies. The molecular docking studies resulted in 15–20 orientations each for the rest of the ligands used in the docking studies. The analysis of protein-ligand interaction between the SARS-CoV-2 PLpro enzyme and EGCG, and theaflavin showed a strong interaction with Tyr²⁶⁸ and Glu¹⁶⁷ whereas, oleuropein and mangiferin interacted with Tyr²⁶⁸ ([Figures 7A–D](#)). As mentioned earlier, Glu¹⁶⁷ plays an important role in the deubiquitination of the enzyme molecular modeling predicted that EGCG, and theaflavin significantly impair the DUB

activity of SARS-CoV-2 PLpro. The ligand-protein fingerprint scan of mangiferin, EGCG, theaflavin, and oleuropein (Figures 8A–D) also shows that these four ligands show interaction with Glu¹⁶⁷ and Tyr²⁶⁸, however mangiferin and oleuropein showed very weak interaction with Glu¹⁶⁷ as compared to EGCG, and theaflavin which is reflected in their low IC₅₀ values for DUB activity.

Discussion

The outbreak of novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing the disease known as COVID-19, is a significant threat to public health globally because of the high rate of infection with the new emerging variants of concerns (Morens and Fauci, 2020; Wang and Yang, 2022c; Tiecco et al., 2022). Although global vaccination is currently ongoing, with the new mutations emerging, there is a greater need to develop therapeutics to protect high-risk populations, especially pregnant women, children, and people living with comorbidity. Currently, only a few antivirals (Paxlovid and Lagevrio) have been approved by the FDA for emergency use to treat COVID-19, however, rebound, mutated, commercialized antivirals remain expensive, and the mutagenic potential of these small molecule antivirals in human cells is challenging their effectiveness (Saravolatz et al., 2022). Previous studies suggested that viral replicative enzymes such as proteases are essential for viral replication (de Leuw and Stephan, 2018), and therefore, may serve as drug targets. The PLpro cleaves the newly generated PP chain auto-proteolytically to generate 3 NSPs required for the viral replication. Besides the protease activity, SARS-CoV-2 PLpro exhibits DUB activity responsible for inhibiting the host's antiviral immune response (Mody et al., 2021; Lewis et al., 2022). Thus, PLpro serves as a drug target to inhibit viral replication and suppress the cytokine storm during SARS-CoV-2 infection.

Our data suggests that EGCG, myricetin, mangiferin, oleuropein, rutin, and theaflavin have the potential to inhibit SARS-CoV-2 PLpro proteolytic and DUB activity, whereas catechin, γ -mangostin and quercetin inhibits only proteolytic activity. This study indicates that the above-mentioned phytochemicals are potential inhibitors against SARS-CoV-2 PLpro proteolytic and deubiquitinase activity.

EGCG is an antioxidant commonly found in green and black tea and is the most potent catechin derivative for antitumor activity and disrupting molecular signaling pathways in breast, pancreatic, prostate, lung, and stomach cancers based on *in vitro* and *in vivo* studies (Chourasia et al., 2021). EGCG also demonstrated antiviral properties in retroviruses such as the Zika virus, influenza A, and Chikungunya virus (Carneiro et al., 2016; Lu et al., 2017; Mou et al., 2020). The anti-SARS-CoV-2 effects of EGCG were reported to be mediated through the inhibition of 3CLpro enzyme (Jang et al., 2020). Mangiferin is a C-glucosyl xanthone (2- β -D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthan-9-one) and a significant component in mango peel and seed with many valuable properties such as antioxidant, anti-microbial, anti-diabetic, anti-allergic, anticancer, hypocholesterolemic, and immunomodulatory effects (Imran et al., 2017). It is also known to inhibit the activation of peroxisome proliferator-activated receptors (Imran et al., 2017). Mangiferin is also known to inhibit the type-I herpes simplex virus (HSV-I) replication in a cell culture model (Imran et al., 2017). Myricetin is a 3, 5, 7, 3', 4', 5'-hexahydroxyflavone abundantly found in fruits, vegetables, tea, and some medicinal plants; however, its primary source is the Chinese bayberry (Zhang et al., 2015; Semwal et al.,

2016). Myricetin draws much consideration because of its several health-beneficial effects: antioxidant, anti-inflammatory, anti-diabetic, anti-Alzheimer, anti-cancer, anti-bacterial, anti-microbial, and anti-viral (Semwal et al., 2016). Its antioxidant activity allows it to serve as a reactive oxygen species scavenger (Semwal et al., 2016). Recent study suggest that myricetin inhibits the SARS-CoV-2 3CLpro enzyme (Xiao et al., 2021). Oleuropein is the primary phenolic compound derived from *Olea europaea*, which also produces olive oil and possesses many pharmacological properties such as antioxidant, anti-inflammatory, anti-atherogenic, anti-cancer, antimicrobial, and antiviral (Omar, 2010). Several epidemiological and clinical studies suggest that theaflavin from black tea has remarkable pharmacological properties, including anti-inflammatory, antioxidant, anti-cancer, anti-obesity, anti-osteoporotic, anti-microbial, and anti-viral effects (Shan et al., 2021). Recent *in vitro* studies suggest that theaflavin inhibits the SARS-CoV-2 3CLpro enzyme (Jang et al., 2020). Rutin is a flavonoid derived from the plant *Ruta graveolens* and is commonly found in teas, apples, and buckwheat. Rutin is commonly known as vitamin P. Rutin has multiple pharmacological activities on different body systems, making it a solid therapeutic phytochemical to fight against several pathological conditions. Additionally, rutin also possesses antiviral activity against retroviruses and viruses such as herpes and hepatitis C and B (Ganeshpurkar and Saluja, 2017).

In conclusion, among the 53 phytochemicals tested, only EGCG, mangiferin, myricetin, oleuropein, theaflavin, and rutin effectively inhibited both proteolytic and DUB activities of PLpro enzyme. Additionally, EGCG, myricetin and theaflavin are known to inhibit 3CLpro, a main protease of SARS-CoV-2 (Jang et al., 2020; Xiao et al., 2021). Our data suggest that EGCG, myricetin and theaflavin also inhibits the SARS-CoV-2 PLpro enzymatic activity, thus providing the evidence of dual target of these molecules to inhibit the SARS-CoV-2 replication. The overall data suggests that the phytochemicals mentioned above have strong potential as antiviral drug candidates to inhibit the SARS-CoV-2 replication and regulate cytokine storm prevalent in COVID-19 patients. Nevertheless, the therapeutic potential of these phytochemicals needs to be further validated by viral challenges and clinical studies to halt the viral spread of SARS-CoV-2 infection.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Author contributions

VM, ST, and SR designed and wrote the manuscript. AK, DL, AS, KC, and RD collected the data on drugs and performed the experiments. All authors reviewed the manuscript.

Acknowledgments

We thank Travis Field, Tu Dang, Handong Ma, and Yan Wu for their technical support during the study. We also thank Deepa Machiah for her critical inputs and proof reading the manuscript. This work was supported by internal funding from Division of Research, PCOM to ST, VM, and RS.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fchem.2022.1100460/full#supplementary-material>

References

- Asrani, P., Eapen, M. S., Chia, C., Haug, G., Weber, H. C., Hassan, M. I., et al. (2021). Diagnostic approaches in COVID-19: Clinical updates. *Expert Rev. Respir. Med.* 15 (2), 197–212. doi:10.1080/17476348.2021.1823833
- Astuti, I., and Ysrafil (2020). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response. *Diabetes metabolic syndrome* 14 (4), 407–412. doi:10.1016/j.dsx.2020.04.020
- Beura, S. K., Panigrahi, A. R., Yadav, P., and Singh, S. K. (2021). Phytochemicals as potential therapeutics for SARS-CoV-2-induced cardiovascular complications: Thrombosis and platelet perspective. *Front. Pharmacol.* 12, 658273. doi:10.3389/fphar.2021.658273
- Calleja, D. J., Lessene, G., and Komander, D. (2022). Inhibitors of SARS-CoV-2 PLpro. *Front. Chem.* 10, 876212. doi:10.3389/fchem.2022.876212
- Carneiro, B. M., Batista, M. N., Braga, A. C. S., Nogueira, M. L., and Rahal, P. (2016). The green tea molecule EGCG inhibits Zika virus entry. *Virology* 496, 215–218. doi:10.1016/j.virol.2016.06.012
- Chakravarti, R., Singh, R., Ghosh, A., Dey, D., Sharma, P., Velayutham, R., et al. (2021). A review on potential of natural products in the management of COVID-19. *RSC Adv.* 11 (27), 16711–16735. doi:10.1039/d1ra00644d
- Cheng, P. W., Ng, L. T., Chiang, L. C., and Lin, C. C. (2006). Antiviral effects of saikosaponins on human coronavirus 229E *in vitro*. *Clin. Exp. Pharmacol. Physiol.* 33 (7), 612–616. doi:10.1111/j.1440-1681.2006.04415.x
- Chourasia, M., Koppula, P. R., Battu, A., Ouseph, M. M., and Singh, A. K. (2021). EGCG, a green tea catechin, as a potential therapeutic agent for symptomatic and asymptomatic SARS-CoV-2 infection. *Molecules* 26 (5), 1200. doi:10.3390/molecules26051200
- de Leuw, P., and Stephan, C. (2018). Protease inhibitor therapy for hepatitis C virus-infection. *Expert Opin. Pharmacother.* 19 (6), 577–587. doi:10.1080/14656566.2018.1454428
- Ganeshpurkar, A., and Saluja, A. K. (2017). The pharmacological potential of rutin. *Saudi Pharm. J.* 25 (2), 149–164. doi:10.1016/j.jsps.2016.04.025
- Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., et al. (2020). How COVID-19 induces cytokine storm with high mortality. *Inflamm. Regen.* 40, 37. doi:10.1186/s41232-020-00146-3
- Imran, M., Arshad, M. S., Butt, M. S., Kwon, J. H., Arshad, M. U., and Sultan, M. T. (2017). Mangiferin: A natural miracle bioactive compound against lifestyle related disorders. *Lipids Health Dis.* 16 (1), 84. doi:10.1186/s12944-017-0449-y
- Jackson, C. B., Farzan, M., Chen, B., and Choe, H. (2021). Mechanisms of SARS-CoV-2 entry into cells. *Nat. Rev. Mol. Cell. Biol.* 23, 3–20. doi:10.1038/s41580-021-00418-x
- Jang, M., Park, Y. I., Cha, Y. E., Park, R., Namkoong, S., Lee, J. I., et al. (2020). Tea polyphenols EGCG and theaflavin inhibit the activity of SARS-CoV-2 3CL-protease *in vitro*. *Evid. Based Complement. Altern. Med.* 2020, 1–7. doi:10.1155/2020/5630838
- Jeon, Y. J., Yoo, H. M., and Chung, C. H. (2010). ISG15 and immune diseases. *Biochim. Biophys. Acta* 1802 (5), 485–496. doi:10.1016/j.bbdis.2010.02.006
- Kikkert, M. (2020). Innate immune evasion by human respiratory RNA viruses. *J. Innate Immun.* 12 (1), 4–20. doi:10.1159/000503030
- Kumar, A., Mishra, D. C., Angadi, U. B., Yadav, R., Rai, A., and Kumar, D. (2021). Inhibition potencies of phytochemicals derived from sesame against SARS-CoV-2 main protease: A molecular docking and simulation study. *Front. Chem.* 9, 744376. doi:10.3389/fchem.2021.744376
- Lewis, D. S. M., Ho, J., Wills, S., Kawall, A., Sharma, A., Chavada, K., et al. (2022). Aloin isoforms (A and B) selectively inhibits proteolytic and deubiquitinating activity of papain like protease (PLpro) of SARS-CoV-2 *in vitro*. *Sci. Rep.* 12 (1), 2145. doi:10.1038/s41598-022-06104-y
- Lin, L. T., Hsu, W. C., and Lin, C. C. (2014). Antiviral natural products and herbal medicines. *J. Tradit. Complement. Med.* 4 (1), 24–35. doi:10.4103/2225-4110.124335
- Lu, J. W., Hsieh, P. S., Lin, C. C., Hu, M. K., Huang, S. M., Wang, Y. M., et al. (2017). Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. *Biochem. biophysical Res. Commun.* 491 (3), 595–602. doi:10.1016/j.bbrc.2017.07.157
- Lv, Z., Cano, K. E., Jia, L., Drag, M., Huang, T. T., and Olsen, S. K. (2022). Targeting SARS-CoV-2 proteases for COVID-19 antiviral development. *Front. Chem.* 9, 819165. doi:10.3389/fchem.2021.819165
- Mahmoudvand, S., and Shokri, S. (2021). Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19. *Scand. J. Immunol.* 94, e13044. doi:10.1111/sji.13044
- McClain, C. B., and Vabret, N. (2020). SARS-CoV-2: The many pros of targeting PLpro. *Signal Transduct. Target Ther.* 5 (1), 223. doi:10.1038/s41392-020-00335-z
- Mody, V., Ho, J., Wills, S., Mawri, A., Lawson, L., Ebert, M., et al. (2021). Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. *Commun. Biol.* 4 (1), 93. doi:10.1038/s42003-020-01577-x
- Morens, D. M., and Fauci, A. S. (2020). Emerging pandemic diseases: How we got to COVID-19. *Cell.* 182 (5), 837–892. doi:10.1016/j.cell.2020.10.022
- Mou, Q., Jiang, Y., Zhu, L., Zhu, Z., and Ren, T. (2020). EGCG induces beta-defensin 3 against influenza A virus H1N1 by the MAPK signaling pathway. *Exp. Ther. Med.* 20 (4), 3017–3024. doi:10.3892/etm.2020.9047
- Omar, S. H. (2010). Oleuropein in olive and its pharmacological effects. *Sci. Pharm.* 78 (2), 133–154. doi:10.3797/scipharm.0912-18
- Ospiuk, J., Azizi, S. A., Dvorkin, S., Endres, M., Jedrzejczak, R., Jones, K. A., et al. (2021). Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. *Nat. Commun.* 12 (1), 743. doi:10.1038/s41467-021-21060-3
- Ratia, K., Kilianski, A., Baez-Santos, Y. M., Baker, S. C., and Mesecar, A. (2014). Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease. *PLoS Pathog.* 10 (5), e1004113. doi:10.1371/journal.ppat.1004113
- Ren, X., Glende, J., Al-Falah, M., de Vries, V., Schwegmann-Wessels, C., Qu, X., et al. (2006). Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. *J. Gen. Virol.* 87 (6), 1691–1695. doi:10.1099/vir.0.81749-0
- Rubin, R. (2022). From positive to negative to positive again—the mystery of why COVID-19 rebounds in some patients who take paxlovid. *JAMA* 327 (24), 2380–2382. doi:10.1001/jama.2022.9925
- Saravolatz, L. D., Depcinski, S., and Sharma, M. (2022). Molnupiravir and nirmatrelvir-ritonavir: Oral COVID antiviral drugs. *Clin. Infect. Dis.*, ciac180. doi:10.1093/cid/ciac180
- Semwal, D. K., Semwal, R. B., Combrinck, S., and Viljoen, A. (2016). Myricetin: A dietary molecule with diverse biological activities. *Nutrients* 8 (2), 90. doi:10.3390/nu8020090
- Shan, Z., Nisar, M. F., Li, M., Zhang, C., and Wan, C. C. (2021). Theaflavin Chemistry and its health benefits. *Oxid. Med. Cell. Longev.* 2021, 1–16. doi:10.1155/2021/6256618
- Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A., et al. (2020). Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. *Nature* 587 (7835), 657–662. doi:10.1038/s41586-020-2601-5
- Srinivasan, V., Brognaro, H., Prabhu, P. R., de Souza, E. E., Gunther, S., Reinke, P. Y. A., et al. (2022). Antiviral activity of natural phenolic compounds in complex at an allosteric site of SARS-CoV-2 papain-like protease. *Commun. Biol.* 5 (1), 805. doi:10.1038/s42003-022-03737-7
- Tiecco, G., Storti, S., Degli Antoni, M., Focà, E., Castelli, F., and Quiros-Roldan, E. (2022). Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: A literature review. *Int. J. Mol. Sci.* 23 (4), 1987. doi:10.3390/ijms23041987
- Tomalka, J. A., Suthar, M. S., Deeks, S. G., and Sekaly, R. P. (2022). Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. *Nat. Immunol.* 23 (3), 360–370. doi:10.1038/s41590-022-01130-4

- Ul Qamar, M. T., Alqahtani, S. M., Alamri, M. A., and Chen, L.-L. (2020). Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. *J. Pharm. Anal.* 10, 313–319. doi:10.1016/j.jpha.2020.03.009
- Wang, Z., and Yang, L. (2020). GS-5734: A potentially approved drug by FDA against SARS-cov-2. *New J. Chem.* 44 (29), 12417–12429. doi:10.1039/d0nj02656e
- Wang, Z., and Yang, L. (2021). Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts. *J. Ethnopharmacol.* 270, 113869. doi:10.1016/j.jep.2021.113869
- Wang, Z., and Yang, L. (2022). Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges. *J. Med. Virol.* 94 (4), 1373–1390. doi:10.1002/jmv.27517
- Wang, Z., and Yang, L. (2022). In the age of Omicron variant: Paxlovid raises new hopes of COVID-19 recovery. *J. Med. Virol.* 94 (5), 1766–1767. doi:10.1002/jmv.27540
- Wang, Z., and Yang, L. (2022). Post-acute sequelae of SARS-CoV-2 infection: A neglected public health issue. *Front. Public Health* 10, 908757. doi:10.3389/fpubh.2022.908757
- Wang, Z., Yang, L., and Song, X.-Q. (2022). Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. *Front. Immunol.* 13, 1015355. doi:10.3389/fimmu.2022.1015355
- Wang, Z., Wang, N., Yang, L., and Song, X.-Q. (2022). Bioactive natural products in COVID-19 therapy. *Front. Pharmacol.* 13, 926507. doi:10.3389/fphar.2022.926507
- Xiao, T., Cui, M., Zheng, C., Wang, M., Sun, R., Gao, D., et al. (2021). Myricetin inhibits SARS-CoV-2 viral replication by targeting M(pro) and ameliorates pulmonary inflammation. *Front. Pharmacol.* 12, 669642. doi:10.3389/fphar.2021.669642
- Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., and Zhou, Y. (2021). The signal pathways and treatment of cytokine storm in COVID-19. *Signal Transduct. Target Ther.* 6 (1), 255. doi:10.1038/s41392-021-00679-0
- Zhang, X., Huang, H., Zhang, Q., Fan, F., Xu, C., Sun, C., et al. (2015). Phytochemical Characterization of Chinese Bayberry (*Myrica rubra* Sieb. et Zucc.) of 17 Cultivars and Their Antioxidant Properties. *Int. J. Mol. Sci.* 16 (6), 12467–12481. doi:10.3390/ijms160612467